Changes in the structure of the ligand or substitutions to AF2 residues in the estrogen receptor make independent contributions to coactivator sensitivity by SRC-1

Journal of Steroid Biochemistry and Molecular Biology

Volumn 67, Issue 3, 1998, Pages 223-232

  Schwartz, Janice A ^a   Brooks, S C ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; REGULATOR PROTEIN; STEROID RECEPTOR COACTIVATOR 1; UNCLASSIFIED DRUG;

ALPHA HELIX; AMINO ACID SUBSTITUTION; ARTICLE; CARBOXY TERMINAL SEQUENCE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; HELA CELL; HUMAN; HUMAN CELL; LIGAND BINDING; PROMOTER REGION; PROTEIN FOLDING; PROTEIN STRUCTURE; RECEPTOR SENSITIVITY; REPORTER GENE; TRANSACTIVATION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; HELA CELLS; HISTONE ACETYLTRANSFERASES; HUMANS; LIGANDS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROMOTER REGIONS (GENETICS); RECEPTORS, ESTROGEN; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 0031764890     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(98)00117-4     Document Type: Article

References (69)

1. Lees J. A., Fawell S. E., Parker M. G. Identification of two transactivation domains in the mouse oestrogen receptor. Nucl. Acids Res. 17:1989;5477-5488.
2. Tora L., White J., Brou C., Tasset D., Webster N., Scheer E., Chambon P. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell. 59:1989;477-487.
3. Tasset D., Tora L., Fromental C., Scheer E., Chambon P. Distinct classes of transcriptional activation domains function by different mechanisms. Cell. 62:1990;1177-1187.
4. Baniahmad C., Nawaz Z., Baniahmad A., Gleeson M. A. G., Tsai M.-J., O'Malley B. W. Enhancement of human estrogen receptor activity by SPT6: a potential coactivator. Mol. Endocrinol. 9:1995;34-43.
5. Horwitz K. B., Jackson T. A., Bain D. L., Richer J. K., Takimoto G. S., Tung L. Nuclear receptor coactivators and corepressors. Mol. Endocrinol. 10:1996;1167-1177.
6. Glass C. K., Rose D. W., Rosenfeld M. G. Nuclear receptor coactivators. Curr. Opin. Cell Biol. 9:1997;222-232.
7. Onate S. A., Tsai S. Y., Tsai M.-J., O'Malley B. W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 270:1995;1354-1357.
8. Halamachi S., Marden E., Martin G., MacKay H., Abbondanza C., Brown M. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science. 264:1994;1455-1458.
9. Cavailles V., Dauvois S., L'Illorset F., Lopez G., Hoare S., Kushner P. J., Parker M. G. Nuclear factor RIP140 modulates transcriptional activation by estrogen receptors. EMBO J. 14:1995;3741-3751.
10. Voegel J. J., Heine M. J. S., Zechel C., Chambon P., Gronemeyer H. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. 15:1996;3667-3675.
11. Hong H., Kohli K., Garabedian M. J., Stallcup M. R. GRIP1 a transcriptional coactivator for the AF2 transactivation domain of steroid, thyroid, retinoic acid, and vitamin D receptors. Mol. Cell Biol. 17:1997;2735-2744.
12. Anzick S. L., Kononen J., Walker R. L., Azorsa D. O., Tanner M. M., Guan X.-Y., Sauter G., Kallioniemi O.-P., Trent J. M., Meltzer P. S. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science. 277:1997;965-968.
13. Chen H., Lin R. J., Schiltz R. L., Chakravarti D., Nash A., Nagy L., Privalsky M. L., Nakatani Y., Evans R. M. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with pCAF and CBP/p300. Cell. 90:1997;569-580.
14. Li H., Gomes P. J., Chen J. D. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc. Natl. Acad. Sci. U.S.A. 94:1997;8479-8484.
15. Torchia J., Rose D. W., Inostroza J., Kamei Y., Westin S., Glass C. K., Rosenfeld M. G. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature. 387:1997;677-684.
16. Takeshita A., Cardona G. R., Koibuchi N., Suen C.-S., Chen W. W. TRAM-1, a novel 160 kDa thyroid hormone receptor activator molecule, exhibits distinct properties from steroid receptor coactivator-1. J. Biol. Chem. 272:1997;27629-27634.
17. Kamei Y., Xu L., Heinzel T., Torchia J., Kurokawa R., Gloss B., Lin S.-C., Heyman R. A., Rose D. W., Glass C. K., Rosenfeld M. G. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell. 85:1996;403-414.
18. Kalkhoven E., Valentine J. E., Heery D. M., Parker M. G. Isoforms of steroid receptor coactivator 1 differ in their ability to potentiate transcription by the oestrogen receptor. EMBO J. 17:1998;232-243.
19. Hayashi Y., Ohmori S., Ito T., Seo H. A splicing variant of steroid receptor coactivator-1 (SRC-1E) the major isoform of SRC-1 to mediate thyroid hormone action. Biochem. Biophys. Res. Commun. 236:1997;83-87.
20. Takeshita A., Yen P. M., Misiti S., Cardona G. R., Liu Y., Chen W. W. Molecular cloning and properties of a full-length putative thyroid hormone receptor coactivator. Endocrinology. 137:1996;3594-3597.
21. Ikonen T., Palvimo J. J., Janne O. A. Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. J. Biol. Chem. 272:1997;29821-29828.
22. Klotzbucher M., Schwerk C., Holewa B., Klein-Hitpass L. Activation of transcription by progesterone receptor involves derepression of activation functions by a cofactor. Mol. Endocrinol. 11:1997;768-778.
23. Jeyakumar M., Tanen M. R., Bagchi M. K. Analysis of the functional role of steroid receptor coactivator-1 in ligand-induced transactivation by thyroid hormone receptor. Mol. Endocrinol. 11:1997;755-767.
24. Masuyama H., Brownfield C. M., St-Arnaud R., MacDonald P. N. Evidence for ligand-dependent intramolecular folding of the AF-2 domain in vitamin D receptor-activated transcription and coactivator interaction. Mol. Endocrinol. 11:1997;1507-1517.
25. Gill R. K., Atkins L. M., Hollis B. W., Bell N. H. Mapping the domains of the interaction of the vitamin D receptor and steroid receptor coactivator-1. Mol. Endocrinol. 12:1998;57-65.
26. Ding X. F., Anderson C. M., Ma H., Hong H., Uht R. M., Kushner P. J., Stallcup M. R. Nuclear receptor binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1(SRC-1): multiple motifs with different binding specificities. Mol. Endocrinol. 12:1998;302-313.
27. Ito M., Yu R. N., Jameson J. L. Steroidogenic factor-1 contains a carboxy-terminal transcriptional activation domain that interacts with steroid receptor coactivator-1. Mol. Endocrinol. 12:1998;290-301.
28. Crawford P. A., Polish J. A., Ganpule G., Sadovsky Y. The activation function-2 hexamer of steroidogenic factor-1 is required, but not sufficient for potentiation by SRC-1. Mol. Endocrinol. 11:1997;1626-1635.
29. Krey G., Braissant O., L'Horset F., Kalkhoven E., Perroud M., Parker M. G., Whali W. Fatty acids, eicdosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 11:1997;779-791.
30. Batistuzzo de Medeiros S. R., Krey G., Hihi A. K., Whali W. Functional interactions between the estrogen receptor and the transcription activator Sp1 regulate the estrogen-dependent transcriptional activity of the vitellogenin A1 io promoter. J. Biol. Chem. 272:1997;18250-18260.
31. McInerney E. M., Tsai J.-J., O'Malley B. W., Katzenellenbogen B. S. Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. Proc. Natl. Acad. Sci. U.S.A. 93:1996;10069-10073.
32. Kraus W. L., Kadonaga J. T. p300 and estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiation. Genes Dev. 12:1998;331-342.
33. Hanstein B., Eckner R., DiRenzo J., Halamachi S., Liu H., Searcy B., Kurokawa R., Brown M. p300 is a component of an estrogen receptor coactivator complex. Proc. Natl. Acad. Sci. U.S.A. 93:1996;11540-11545.
34. Yao T.-P., Ku G., Zhou N., Scully R., Livingston D. M. The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. Proc. Natl. Acad. Sci. U.S.A. 93:1996;10626-10631.
35. Smith C. L., Nawaz Z., O'Malley B. W. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol. 11:1997;657-667.
36. Yang X.-J., Ogryzko V. V., Nishikawa J.-I., Howard B. H., Nakatani Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature. 382:1996;319-324.
37. Ogryzko V. V., Schiltz R. L., Russanova V., Howard B. H., Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 87:1996;953-959.
38. Kurokawa R., Kalafus D., Ogliastro M.-H., Kioussi C., Xu L., Torchia J., Rosenfeld M. G., Glass C. K. Differential use of CREB binding protein-coactivator complexes. Science. 279:1998;700-703.
39. Korzus E., Torchia J., Rose D. W., Xu L., Kurokawa R., McInerney E. M., Mullen T.-M., Glass C. K., Rosenfeld M. G. Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science. 279:1998;703-707.
40. Spencer T. E., Jenster G., Burcin M. M., Allis C. D., Zhou J., Mizzen C. A., McKenna N. J., Onate S. A., Tsai S. Y., Tsai M.-J., O'Malley B. W. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature. 389:1997;194-198.
41. Bannister A. J., Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature. 384:1996;641-643.
42. Heery D. M., Kalkhoven E., Hoare S., Parker M. G. A signature motif in coactivators mediates binding to nuclear receptors. Nature. 387:1997;733-736.
43. LeDouarin B., Zechel C., Garnier J.-M., Lutz Y., Tora L., Pierrat B., Heery D., Gronemeyer H., Chambon P., Losson R. TIF1, a potential mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO J. 14:1995;2020-2033.
44. Voegel J. J., Heine M. J. S., Tini M., Vivat V., Chambon P., Gronemeyer H. The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO J. 17:1998;507-519.
45. Gandini O., Kohno H., Curtis S., Korach K. S. Two transcription activation functions in the amino terminus of the mouse estrogen receptor that are affected by the carboxy terminus. Steroids. 62:1997;508-515.
46. Masuyama H., Brownfield C. M., St-Arnaud R., MacDonald P. N. Evidence for ligand-dependent intramolecular folding of the AF-2 domain in vitamin D receptor-activated transcription and coactivator interaction. Mol. Endocrinol. 11:1997;1507-1517.
47. Henttu P. M. A., Kalkhoven E., Parker M. G. AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors. Mol. Cell. Biol. 17:1997;1832-1839.
48. Lazennec G., Ediger T. R., Petz L. N., Nardulli A. M., Katzenellenbogen B. S. Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DAN and coregulator interactions and receptor conformational changes. Mol. Endocrinol. 11:1997;1375-1386.
49. Brzozowski A. M., Pike A. C. W., Dauter Z., Hubbard R. E., Bonn T., Engstrom O., Ohman L., Greene G., Gustafsson J.-A., Carlquist M. Molecular basis of agonism in the oestrogen receptor. Nature. 389:1997;753-758.
50. Wagner R. L., Apriletti J. W., McGrath M., West B., Baxter J. D., Fletterick R. J. A structural role for hormone in the thyroid hormone receptor. Nature. 378:1995;690-697.
51. Renaud J. P., Rochel N., Ruff M., Vivat V., Chambon P., Gronemeyer H., Moras D. Crystal structure of the RARγ ligand binding domain bound to all-trans retinoic acid. Nature. 378:1995;681-689.
52. Bourguet W., Ruff M., Chambon P., Gronemeyer H., Moras D. Crystal structure of the human nuclear receptor RXR-α Nature. 375:1995;377-382.
53. Pilat M. J., Hafner M., Kral L. G., Brooks S. C. Differential induction of pS2 and cathepsin D mRNAs by structurally altered estrogens. Biochemistry. 32:1993;7009-7015.
54. Ekena K., Weiss K. E., Katzenellenbogen B. S. Identification of amino acids in the hormone binding domain of the human estrogen receptor important for estrogen binding. J. Biol. Chem. 271:1996;20053-20059.
55. Ekena K., Weiss K. E., Katzenellenbogen B. S. Different residues in the human estrogen receptor are involved in the recognition of structurally diverse estrogens and antiestrogens. J. Biol. Chem. 272:1997;5069-5075.
56. Montano M. M., Ekena K., Krueger K. D., Keller A. L., Katzenellenbogen B. S. Human estrogen receptor ligand activity inversion mutants: antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Mol. Endocrinol. 10:1996;230-242.
57. Schwartz J. A., Brooks S. C. Neutral mutations to three acidic AF2 residues in the mouse estrogen receptor confer agonist activity to A-ring isomers of estradiol. J. Steroid Biochem. Mol. Biol. 62:1997;173-184.
58. Danielian P., White R., Lees J., Parker M. G. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J. 11:1992;1025-1033.
59. Mafoudi A., Roulet E., Dauvois S., Parker M. G., Wahli W. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc. Natl. Acad. Sci. U.S.A. 92:1995;4206-4210.
60. Katzenellenbogen J. A., O'Malley B. W., Katzenellenbogen B. S. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol. Endocrinol. 10:1996;119-131.
61. Palomino E., Heeg M. J., Horwitz J. P., Brooks S. C. Binding, X-ray, and NMR studies of three A-ring isomers of natural estradiol. J. Steroid Biochem. 35:1990;219-221.
62. VanderKuur J. A., Hafner M. S., Christman J. K., Brooks S. C. Effects of estradiol-17β analogs on activation of ERE regulated CAT expression. Biochemistry. 32:1993;7016-7021.
63. Lees J. A., Fawell S. E., Parker M. G. Identification of two transactivation domains in the mouse oestrogen receptor. Nucl. Acids Res. 17:1989;5477-5489.
64. Fawell S. E., Lees J. A., Parker M. G. A proposed consensus steroid binding sequence: a reply. Mol. Endocrinol. 3:1989;1002-1005.
65. Danielian P. S., White R., Hoare S. A., Fawell S. E., Parker M. G. Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. Mol. Endocrinol. 7:1993;232-240.
66. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
67. Schwartz J. A., Skafar D. F. Ligand-mediated modulation of estrogen receptor conformation by estradiol analogs. Biochemistry. 32:1993;10109-10115.
68. Feng W., Ribeiro R. C. J., Wagner R. L., Nguyen H., Apriletti J. W., Fletterick R. J., Baxter J. D., Kushner P. J., West B. L. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science. 280:1998;1747-1749.
69. Vivat V., Zechel C., Wurtz J.-M., Bourguet W., Kagechika H., Umemiya H., Shudo K., Moras D., Gronemeyer H., Chambon P. A mutation mimicking ligand-induced conformational change yields a constitutive RXR that senses allosteric effects in heterodimers. EMBO J. 16:1997;5697-5709.